Exploring the efficacy and safety of Chazhu Xiaozhi decoction in the treatment of metabolic dysfunction-associated steatotic liver disease: a randomized, quadruple-blind, placebo-controlled clinical trial
Traditional Medicine Research · 2027 · 12 (8) · 55
DOI: 10.53388/tmr2027055 ↗Kurz gefasst
Fachartikel in der Zeitschrift Traditional Medicine Research, 2027. Verfasst von Chong Chen und 11 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Metabolic dysfunction-associated steatotic liver disease (MASLD) has become the leading cause of chronic liver disease. Chazhu Xiaozhi decoction (CXD) is a prescription formulated based on the ethnopharmacological use of Camellia Sinensis Radix. This study aimed to evaluate the short-term efficacy and safety of CXD in adults with MASLD through a single-center, randomized, quadruple-blind, placebo-controlled trial.
Methods
Between July 2024 and May 2025, a total of 70 participants were enrolled in this study. All participants received a baseline dietary intervention and were randomly assigned in a 1:1 ratio to either Group A (control) or Group B (CXD) for an eight-week intervention. The primary efficacy outcome was the change in the controlled attenuation parameter (CAP). Key secondary outcomes included the traditional Chinese medicine (TCM) symptom score, body weight, and waist circumference, while liver function, lipid metabolism, and glucose metabolism parameters were analyzed as exploratory outcomes.
Results
After eight weeks of treatment, a significant reduction in hepatic fat content was observed in both groups, with the CXD group demonstrating a significantly lower CAP value compared to the control group. In addition, CXD was also associated with greater improvements in the TCM syndrome score and selected anthropometric outcomes. Exploratory analyses indicated favorable changes in several liver function, lipid metabolism, and glucose metabolism parameters in the CXD group. No clinically meaningful abnormalities were identified in the measured routine blood, liver, or renal biochemical parameters, and no treatment-emergent adverse events were reported during the study.
Conclusions
CXD has demonstrated preliminary short-term efficacy in the treatment of MASLD and had an acceptable short-term safety profile, positioning it as a promising TCM-based intervention for the management of MASLD.
Zitieren
APA
Chen, C., Wu, X., Pan, X., Wang, J., Gu, S., Wang, Y., Shang, J., Liu, X., Lin, L., Zhang, K., Zheng, Y., & Li, Y. (2027). Exploring the efficacy and safety of Chazhu Xiaozhi decoction in the treatment of metabolic dysfunction-associated steatotic liver disease: a randomized, quadruple-blind, placebo-controlled clinical trial. Traditional Medicine Research, 12(8), 55. https://doi.org/10.53388/tmr2027055
Vancouver
Chen C, Wu X, Pan X, Wang J, Gu S, Wang Y, et al. Exploring the efficacy and safety of Chazhu Xiaozhi decoction in the treatment of metabolic dysfunction-associated steatotic liver disease: a randomized, quadruple-blind, placebo-controlled clinical trial. Traditional Medicine Research. 2027;12(8):55. doi:10.53388/tmr2027055
BibTeX
@article{Chen2027,
author = {Chen, Chong and Wu, Xing-Li and Pan, Xiang-Xue and Wang, Jun-Min and Gu, Si-Min and Wang, Yan-Ping and Shang, Jia-Rong and Liu, Xiao-Lin and Lin, Liu-Bing and Zhang, Ke-Hui and Zheng, Yi-Yuan and Li, Yong},
title = {Exploring the efficacy and safety of Chazhu Xiaozhi decoction in the treatment of metabolic dysfunction-associated steatotic liver disease: a randomized, quadruple-blind, placebo-controlled clinical trial},
journal = {Traditional Medicine Research},
year = {2027},
volume = {12},
number = {8},
pages = {55},
doi = {10.53388/tmr2027055}
}
EUVIMED